// App-Quantinova.ai

3742 : RUNX1 Is Required For Maintenance Of Established T-ALL Blasts

Researchers

Presenter

  • Christopher R Jenkins

Principal Investigators

  • Olena O Shevchuk

  • Hongfang Wang

  • Vincenzo Giambra

  • Samuel D Gusscott

  • Jon C. Aster

  • Andrew P Weng

Medical Centers

  • Department of Medicine, Brigham and Women's Hospital, Boston, MA

  • Terry Fox Laboratory, BC Cancer Agency, Vancouver, BC, Canada

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • Neurogenic locus notch homolog protein 1

  • Cyclin dependent kinase inhibitor 1B

  • Phosphatase and tensin homolog

  • Cyclin dependent kinase inhibitor 1A

  • ETV6-RUNX1

  • Insulin-like growth factor 1 receptor

  • TAL BHLH Transcription Factor 1, Erythroid Differentiation Factor

Drug/Treatment

  • Aster

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved